Hemoglobinopathies Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2021 to 2027

The Global Hemoglobinopathies Market size was valued at USD 7.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 10% from 2021 to 2027.

Hemoglobinopathy is a genetic disorder that causes structural abnormalities in the hemoglobin molecule, particularly defective globin chains. Hemoglobinopathy is a hereditary single-gene disease, with sickle cell disease being the most common type. The prevalence of hemoglobinopathy is high in Africa, Southeast Asia, and the Mediterranean basin. If left untreated, serious cases of hemoglobinopathy lead to anemia, organ dysfunction, or death. Gel electrophoresis and complete blood count are used as diagnostic tests to determine the presence of hemoglobinopathy. There is no permanent cure for this disease. This has increased the demand for new product innovations in the pharmaceutical sector.

Market Segments

By Indication Type

• Sickle Cell Disease
• Alpha Thalassemia
• Beta Thalassemia

By End-User

• Hospitals
• Diagnostic Laboratories
• Clinics

By Test Type

• Red blood cell (RBC) count test
• Genetic testing, hemoglobin by high performance liquid chromatography (HPLC) test
• Hemoglobin isoelectric (Hb IEF) focusing
• Hemoglobin electrophoresis (Hb ELP) test
• Hemoglobin solubility test.

Key Players

Key industry players comprise Alnylam Pharmaceuticals, Gamida Cell, Biogen Idec, AcceleronPharma, Sangamo BioSciences, Anthera Pharmaceuticals, Global Blood Therapeutics, Genetix Pharmaceuticals, Mast Therapeutics, Prolong Pharmaceuticals, Emmaus Medical, Calgene Corporation, Invenux, Optinova Ab, and HemaQuest Pharmaceuticals.

Scope of the Report

The research study analyzes the global Hemoglobinopathies industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Hemoglobinopathies Market Report

1. What was the Hemoglobinopathies Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2021-2027).

2. What will be the CAGR of the Hemoglobinopathies Market during the forecast period (2021-2027)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2021? How these segments are expected to grow during the forecast period (2021-2027).
4. Which manufacturer/vendor/players in the Hemoglobinopathies Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.